Inverted urothelial papilloma

Summary

Inverted urothelial papilloma (MONDO:0021109) is a disease. A subtype of inverted transitional cell papilloma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	inverted urothelial papilloma
Mondo ID	MONDO:0021109
NCIT	C6192
UMLS	C1334282
MedGen	233583
Anatomy (UBERON)	UBERON:0000365
Is cancer (heuristic)	no

Also known as: inverted papilloma of urinary tract · inverted urothelial papilloma · IUP · urinary tract inverted papilloma · urothelium inverted papilloma

Disease family

This is a subtype of inverted transitional cell papilloma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › papillary epithelial neoplasm › papilloma › inverted papilloma › inverted transitional cell papilloma › inverted urothelial papilloma

Subtypes (4): renal pelvis inverted papilloma, urinary bladder inverted papilloma, urethra inverted papilloma, ureter inverted papilloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.